> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Acadia Gets Fast Track for Alzheimer’s Psychosis Drug
- URL: https://www.fdaweb.com/acadia-gets-fast-track-for-alzheimers-psychosis-drug/
- Published: 2026-07-21T12:00:00.000Z
- Updated: 2026-09-14T13:43:16.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5161491

FDA has granted Acadia Pharmaceuticals a Fast Track designation for remlifanserin, an investigational, highly selective, 5-HT2A receptor inverse agonist for treating hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP).

Acadia says enrollment has been complete in the company’s Phase 2 RADIANT study that is evaluating remlifanserin as a treatment for hallucinations and delusions associated with ADP. The company says it expects to report topline results by the end of October 2026\. ‘Consistent with RADIANT’s operationally seamless design, screening and enrollment are underway in the Phase 3 studies,” it adds.

Remlifanserin is believed to reduce hallucinations and delusions through selective 5-HT2A receptor inverse agonism, potentially restoring excitatory/inhibitory balance without direct dopamine blockade and avoiding the common safety and tolerability issues associated with atypical antipsychotics, according to the company.